Egger ME, Armstrong E, Martin RCG, et al. - Researchers examined the short- and long-term outcomes associated with transarterial chemoembolization (TACE) vs transarterial radioembolization (TARE) with yttrium-90 (y-90) for unresectable neuroendocrine liver metastases (NELM). From 2000-2018, they identified 248 patients with NELM who were undergoing transarterial therapies at two academic medical centers; 197 (79%) received TACE and 51 (21%) received TARE. While carcinoid syndrome, larger tumors, and higher chromogranin A levels were more frequently reported among patients who underwent TACE, no difference was observed in tumor differentiation, primary site, bilobar disease, or synchronous presentation. This retrospective multi-institutional analysis suggests that for unresectable NELM, both TACE and TARE with Y-90 are safe and effective liver-directed therapies. Although TARE was linked with a shorter length of hospital stay, TACE resulted in improved short term disease control rate, and both were comparable concerning long term outcomes.